Flagship commits $50M to new startup that scours viral proteins for new drugs - Endpoints News
endpts.comSubmitted by endpointsnews6292 in health
In the midst of the Covid-19 pandemic, while most scientists were busy plotting new ways to combat viruses, one startup quietly began a counterintuitive campaign: getting viruses to work for us, instead of against us. Now, after three years in stealth, Prolog…